CROs offering Target Identification & Validation with Biologics (Monoclonal Antibodies)
17 published
17 published CROs match Target Identification & Validation and Biologics (Monoclonal Antibodies).
Locations in this set include United States, China, India, United Kingdom, 30 countries, and 30+ countries.
Capabilities that show up most often in this set: Discovery Research, In Vitro Pharmacology, In Vivo Efficacy Models, In Vivo PK / PD Studies, and Preclinical In Vivo Studies.
Matching companies
Aliri BioanalysisBioanalytical CRO specializing in PK/PD, biomarker, and spatial imaging services across discovery through Phase 3 clinical trials, with 20+ years of regulatory expertise.
Aragen Life SciencesGlobal CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
Axcelead Drug Discovery Partners, Inc.Axcelead provides integrated drug discovery research services to pharmaceutical companies, biotech ventures, and academic institutions. Founded in 2017 from Takeda's drug discovery research base, the company offers expertise across small molecules, nucleic acids, antibodies, and multiple therapeutic modalities.
BioDuro-SundiaBioDuro-Sundia is a contract research, development, and manufacturing organization (CRDMO) with 30 years of expertise providing integrated drug discovery, development, and manufacturing services from target identification through IND submission.
CertaraCertara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.
ChemPartnerGlobal preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide.
Frontage LaboratoriesGlobal pharmaceutical development organization offering integrated drug discovery, preclinical safety/toxicology, DMPK, bioanalytical, and clinical trial services across 28 sites with 2,200 employees and 200+ FDA inspections.
GemPharmatechGemPharmatech develops and supplies genetically engineered mouse models (GEMMs) and preclinical research services using CRISPR/Cas9 and gene-editing technologies, with a library of 25,000+ mouse strains including KO/cKO, humanized, and immunodeficient models.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Proone LabsProone Labs provides preclinical pharmacology, drug discovery, and regulatory support services to biotech startups, traditional pharma, and in-silico companies. The team has delivered 30+ assays, 50+ cell lines, and supported 4 FDA drug approvals across multiple therapeutic areas.
ProtheragenSpecialized preclinical CRO dedicated to obesity research, offering comprehensive animal models, pharmacokinetic/pharmacodynamic studies, bioanalysis, and safety assessment for anti-obesity drug development.
Rapid Novor Inc.Rapid Novor is a contract research organization specializing in antibody discovery, characterization, and sequencing services powered by mass spectrometry, HDX-MS, and surface plasmon resonance.
Reaction BiologyGlobal preclinical CRO specializing in kinase drug discovery, cell-based assays, in vivo pharmacology, and immuno-oncology with 1,000+ cell lines and hundreds of validated protein targets across US and EU facilities.
SelvitaSelvita is an integrated drug discovery and development service provider offering comprehensive solutions from target validation through preclinical candidate nomination and clinical manufacturing, with expertise in small molecules, antibodies, and protein degraders.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
TRiCBIOTRiCBIO provides human organoid research services for efficacy, safety, mechanism and immune-context studies using PDO 2.0 and ALI platforms, supporting biopharma and CRO teams in candidate evaluation and translational research.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/target-identification-validation/biologics-monoclonal-antibodies.md